1-[3-(2-methylpropoxy)phenyl]ethan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[3-(2-methylpropoxy)phenyl]ethan-1-one
• 英文别名: 1-(3-Isobutoxyphenyl)ethanone；1-[3-(2-methylpropoxy)phenyl]ethanone
• 化学式: C₁₂H₁₆O₂
• mdl: MFCD02254122
• 分子量: 192.258
• InChiKey: WWVWBUVCCKDSNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  溴代异丁烷 、 3-羟基苯乙酮 在 potassium phosphate 作用下， 以 二甲基亚砜 为溶剂， 生成 1-[3-(2-methylpropoxy)phenyl]ethan-1-one
  参考文献：
  名称：

  HETEROCYCLIC INHIBITORS OF MCT4

  摘要：

  本文披露了一些化合物和组合物，适用于治疗由MCT4介导的疾病，如增殖性和炎症性疾病，其结构如下所示： 还提供了在人类或动物主体中抑制MCT4活性的方法。

  公开号：

  US20180162822A1

文献信息

• [EN] MCT4 INHIBITORS FOR TREATING DISEASE<br/>[FR] INHIBITEURS DE MCT4 POUR LE TRAITEMENT DE MALADIES
  申请人：VETTORE LLC

  公开号：WO2016201426A1

  公开（公告）日：2016-12-15

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一种在治疗MCT4介导的疾病中有用的化合物和组合物，如增殖性和炎症性疾病，其具有Formula I的结构：还提供了在人类或动物主体中抑制MCT4活性的方法。
• Calcium receptor active compounds
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20030176485A1

  公开（公告）日：2003-09-18

  A novel calcium receptor active compound having the formula is provided: Ar 1 —[CR 1 R 2 ] p —X—[CR 3 R 4 ] q —[CR 5 R 6 ]—NR 7 —[CR 8 R 9 ]—Ar 2 wherein: Ar 1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl) amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are, for example, hydrogen or alkyl; Ar 2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.

  提供一种具有以下式子的新型钙受体活性化合物：Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2其中：Ar1选自芳基、杂芳基、双(芳基甲基)氨基、双(杂芳基甲基)氨基和芳基甲基(杂芳基甲基)氨基的群；X选自氧、硫、亚磺酰基、磺酰基、羰基和氨基的群；R1、R2、R3、R4、R5、R6、R7、R8和R9例如是氢或烷基；Ar2选自芳基和杂芳基的群；p为0至6的整数，包括0和6；q为0至14的整数，包括0和14。
• Calcium receptor-active compounds
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20020107406A1

  公开（公告）日：2002-08-08

  A novel calcium receptor active compound having the formula is provided: Ar 1 —[CR 1 R 2 ] p —X—[CR 3 R 4 ] q —[CR 5 R 6 ]—NR 7 —[CR 8 R 9 ]—Ar 2 wherein: Ar 1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl) amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are, for example, hydrogen or alkyl; Ar 2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.

  提供了具有以下结构的一种新型钙受体活性化合物：Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2其中：Ar1选择自芳基、杂芳基、双(芳基甲基)氨基、双(杂芳基甲基)氨基和芳基甲基(杂芳基甲基)氨基的群；X选择自氧、硫、亚硫基、磺酰基、羰基和氨基的群；R1、R2、R3、R4、R5、R6、R7、R8和R9例如是氢或烷基；Ar2选择自芳基和杂芳基的群；p是从0到6的整数，包括0和6；q是从0到14的整数，包括0和14。
• CALCIUM RECEPTOR-ACTIVE COMPOUNDS
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP0933354A1

  公开（公告）日：1999-08-04

  A novel calcium receptor active compound having the formula is provided:         Ar1-[CR1 R2]P-X-[CR3R4]q-[CR5R6]-NR7-[CR8R9]-Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.

  本研究提供了一种具有以下式子的新型钙受体活性化合物： Ar1-[CR1 R2]P-X-[CR3R4]q-[CR5R6]-NR7-[CR8R9]-Ar2 其中 Ar1 选自由芳基、杂芳基、双(芳基甲基)氨基、双(杂芳基甲基)氨基和芳 甲基(杂芳基甲基)氨基组成的组； X 选自氧、硫、亚砜基、磺酰基、羰基和氨基组成的组； R1、R2、R3、R4、R5、R6、R7、R8 和 R9 例如为氢或烷基； Ar2 选自芳基和杂芳基组成的组； p 是 0 至 6（包括 6）的整数；以及 q 是 0 至 14（包括 14）的整数。
• MCT4 inhibitors for treating disease
  申请人：Vettore, LLC

  公开号：US10202350B2

  公开（公告）日：2019-02-12

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文公开了用于治疗 MCT4 介导的疾病（如增殖性和炎症性疾病）的化合物和组合物，其结构如式 I 所示： 还提供了抑制人或动物体内 MCT4 活性的方法。